All In Biotech

Drug Trial Radar · NCT01600079

ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX™

Last checked: Nov 20, 2026Latest source record: Jul 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,505,647

Actual

Start

May 15, 2012

Primary completion

Oct 16, 2020

Study completion Oct 16, 2020

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Kaiser Permanente
First posted
May 16, 2012

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.

Conditions

  • Herpes Zoster
  • Shingles

Interventions

  • ZOSTAVAX™Biological

    ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79 ≥80) at VaccinationTime frame: 10 years
  2. Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts by Time since VaccinationTime frame: 10 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.